Biogen (NASDAQ:BIIB) Price Target Increased to $363.00 by Analysts at Royal Bank of Canada
Biogen (NASDAQ:BIIB – Free Report) had its target price lifted by Royal Bank of Canada from $351.00 to $363.00 in a report issued on Thursday, Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock. Other analysts have also recently issued reports about the company. Scotiabank started coverage on Biogen in a […]
More Stories
Dolly Parton, queen of country music, dies at 80
By Reuters Aug 25 (Reuters) – Dolly Parton was around six when she wrote her first song: “Little Tiny Tasseltop,”...
Canada’s Dollar-for-Dollar Tariff Response Exposes a Trade Relationship America Should Have Reexamined Decades Ago
By Stephen Zogopoulos, USNN World News Canada has now formally answered Washington’s latest tariffs with what it calls a “dollar-for-dollar,...
South Carolinians Go to Polls for Key Republican Senate Primary
By Joseph Lord CHARLESTON, S.C.—South Carolina voters will head to the polls today to make their pick in a runoff...
Iran Vows to Retaliate After US Rolls Out ‘Economic D-Day’ Sanctions
By Owen Evans Iran has promised to retaliate against the United States after Washington rolled out an “economic D-Day” sanctions...
ICE Arrests More Than 1,300 Illegal Immigrants in Virginia, Maryland in 2-Week Operation
By Aldra Fredly Immigration and Customs Enforcement (ICE) arrested more than 1,300 illegal immigrants during a two-week operation in Virginia...
Bessent Warns China, Others Not to Test US Resolve on Iran Sanctions
By Andrew Moran and Emel Akan Bessent, at an Aug. 24 news conference, unveiled the contours of the administration’s sweeping...